World's Best Scientists 2026 revealed!
Award Badge
Biology and Biochemistry
Germany
2026
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Biology and Biochemistry

D-Index
144
Citations
94101
World Ranking
226
National Ranking
14

Medicine

D-Index
156
Citations
125211
World Ranking
901
National Ranking
43

Research.com Recognitions

  • 2026 - Research.com Biology and Biochemistry in Germany Leader Award
  • 2026 - Research.com Medicine in Germany Leader Award
  • 2025 - Research.com Biology and Biochemistry in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Hans-Peter Hartung is affiliated with Heinrich Heine University Düsseldorf in Germany. Their research primarily spans the field of Medicine, with a focus on several subfields including Pathology and Forensic Medicine, Neurology, Oncology, Rheumatology, and Immunology.

The scientist's work is concentrated on key research topics such as Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Neuroinflammation and Neurodegeneration Mechanisms, Rheumatoid Arthritis Research and Therapies, Cytokine Signaling Pathways and Interactions, Systemic Sclerosis and Related Diseases, and Immunotherapy and Immune Responses.

Frequent co-authors collaborating with Hans-Peter Hartung include Orhan Aktaş, Xavier Montalbán, Friedemann Paul, Bruce Cree, and Peter A. Calabresi.

Hans-Peter Hartung has published extensively in notable scientific venues. Regular publication venues include The Lancet Neurology, Brain, Multiple Sclerosis Journal, Neurology, and EBioMedicine.

Recent papers by Hans-Peter Hartung include:

  • "APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies" (2021) in Neurology
  • "Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial" (2020) in The Lancet Neurology
  • "Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial" (2020) in The Lancet Neurology
  • "The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history" (2020) in Brain
  • "Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study" (2021) in Multiple Sclerosis Journal

Best Publications

  • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

    W. Ian McDonald;Alistair Compston;Gilles Edan;Donald E Goodkin

  • Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

    Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll

  • Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

    Chris H. Polman;Stephen C. Reingold;Gilles Edan;Massimo Filippi

  • Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

    Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer

  • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

    Jeffrey A. Cohen;Frederik Barkhof;Giancarlo Comi;Hans Peter Hartung

  • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold

  • Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

    Giancarlo Comi;Massimo Filippi;Frederik Barkhof;Luca Durelli

  • Guillain–Barré Syndrome

    Nobuhiro Yuki;Hans-Peter Hartung

  • Chemotherapy-induced peripheral neuropathy.

    Stefan Quasthoff;Hans Peter Hartung

  • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

    Jeffrey A. Cohen;Alasdair J. Coles;Douglas L. Arnold;Christian Confavreux

  • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

    Alasdair J. Coles;Cary L. Twyman;Douglas L. Arnold;Jeffrey A. Cohen

  • Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

    Hans-Peter Hartung;Richard Gonsette;Nikolaus Konig;Hubert Kwiecinski

  • Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds

    Franz Fazekas;Reinhold Kleinert;Gudrun Roob;Gertrude Kleinert

  • ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

    X. Montalban;R. Gold;A. J. Thompson;S. Otero‐Romero

  • Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.

    R Gold;M Schmied;G Giegerich;H Breitschopf

  • Electrophysiological classification of guillain-barré syndrome: Clinical associations and outcome

    R. D. M. Hadden;D. R. Cornblath;R. A. C. Hughes;J. Zielasek

  • Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

    Jerold Chun;Hans-Peter Hartung

  • Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome

    Rac Hughes;AV Swan;Cornblath;HP Hartung

  • Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

    Dawn Langdon;M P Amato;J Boringa;B Brochet

  • Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

    L. Kappos;C.H. Polman;M.S. Freedman;G. Edan

Frequent Co-Authors

Bernd C. Kieseier
Bernd C. Kieseier Novartis (Switzerland)
Orhan Aktas
Orhan Aktas Heinrich Heine University Düsseldorf
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Bernhard Hemmer
Bernhard Hemmer Technical University of Munich
Eva Havrdova
Eva Havrdova Charles University
Krzysztof Selmaj
Krzysztof Selmaj University of Warmia and Mazury in Olsztyn
Douglas L. Arnold
Douglas L. Arnold Montreal Neurological Institute and Hospital
Giancarlo Comi
Giancarlo Comi Vita-Salute San Raffaele University
Olaf Stüve
Olaf Stüve The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry in the USA opens doors to a wide range of careers in healthcare and research. Many students choose to expand their expertise with flexible education options, like a cheap online MBA healthcare administration program. This degree can boost leadership opportunities in medical and pharmaceutical organizations.

Another pathway is medical coding, which plays a vital role in healthcare. Salary expectations for this field are appealing, as detailed in this overview of medical coding salary benchmarks. Getting certified is important; candidates often debate ccs vs cpc certification to determine which is best for their career trajectory and earning potential.

If you’re interested in allied health, understanding the medical coding job outlook is crucial. The demand for skilled billers and coders is strong, offering job security and diverse work environments. These pathways complement biology and biochemistry backgrounds, providing practical and rewarding career options beyond the lab.

Best Scientists Citing Hans-Peter Hartung

Trending Scientists